MX2022008277A - Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. - Google Patents
Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.Info
- Publication number
- MX2022008277A MX2022008277A MX2022008277A MX2022008277A MX2022008277A MX 2022008277 A MX2022008277 A MX 2022008277A MX 2022008277 A MX2022008277 A MX 2022008277A MX 2022008277 A MX2022008277 A MX 2022008277A MX 2022008277 A MX2022008277 A MX 2022008277A
- Authority
- MX
- Mexico
- Prior art keywords
- serum
- methods
- stratum corneum
- transdermal delivery
- gel compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 210000002966 serum Anatomy 0.000 title abstract 2
- 210000000434 stratum corneum Anatomy 0.000 title abstract 2
- 230000037317 transdermal delivery Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En la presente se describen composiciones de gel para la liberación transdérmica mejorada de un ingrediente activo en un suero de un sujeto a través de la producción de un depósito del ingrediente activo en el estrato córneo del sujeto. En la presente también se describen métodos para usar la composición de gel para mejorar al menos parcialmente una afección, y kits que comprenden la composición de gel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662275955P | 2016-01-07 | 2016-01-07 | |
US201662371670P | 2016-08-05 | 2016-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022008277A true MX2022008277A (es) | 2022-08-04 |
Family
ID=58463817
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008467A MX2018008467A (es) | 2016-01-07 | 2017-01-06 | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. |
MX2022008277A MX2022008277A (es) | 2016-01-07 | 2018-07-06 | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018008467A MX2018008467A (es) | 2016-01-07 | 2017-01-06 | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20170196896A1 (es) |
EP (2) | EP3399963B1 (es) |
JP (3) | JP7055754B2 (es) |
KR (1) | KR20180117103A (es) |
CN (1) | CN108712901A (es) |
AU (2) | AU2017206048B2 (es) |
BR (1) | BR122023025444A2 (es) |
CA (1) | CA3010829A1 (es) |
ES (1) | ES2949053T3 (es) |
GB (1) | GB2551598B (es) |
IL (2) | IL300437A (es) |
MX (2) | MX2018008467A (es) |
WO (1) | WO2017120492A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
IL310755A (en) * | 2017-06-22 | 2024-04-01 | Viramal Ltd | An emulsion preparation that includes danzol for use in the treatment of endometrial conditions |
WO2019093780A1 (ko) * | 2017-11-10 | 2019-05-16 | (주)아모레퍼시픽 | 바이겔 타입의 화장료 조성물 |
CN108635330B (zh) * | 2018-04-17 | 2021-11-30 | 上海普特生物科技有限公司 | 一种长效缓释黄体酮凝胶剂组合物 |
GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
CA3123928C (en) * | 2018-07-30 | 2023-11-14 | Biothea Pharma, Inc. | Crystalline epinephrine malonate salt |
CA3117842A1 (en) | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
EP3659583B1 (en) * | 2018-11-30 | 2023-06-07 | Viramal Limited | A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent |
EP3922235A1 (en) * | 2020-06-11 | 2021-12-15 | Viramal Limited | A hydroalcoholic gel and a method of manufacturing said gel |
WO2022167359A1 (en) * | 2021-02-02 | 2022-08-11 | DuPont Nutrition USA, Inc. | An aqueous gel composition comprising an ethylcellulose |
CN112970804A (zh) * | 2021-03-29 | 2021-06-18 | 陕西农产品加工技术研究院 | 一种基于甘油二酯油凝胶的枸杞面包及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US618323A (en) | 1899-01-24 | Berndt e | ||
FR2739559B1 (fr) * | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Gel pour hormonotherapie locale de la secheresse vaginale |
WO1999062497A1 (en) * | 1998-06-03 | 1999-12-09 | Aiache Jean Marc | Stable gel mixture in the form of a mixture of oleogel and aqueous gel |
FR2779438B1 (fr) * | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
AU2006212021B2 (en) * | 2005-02-10 | 2010-09-30 | Orexo Ab | Pharmaceutical compositions useful in the transmucosal administration of drugs |
DE102005037844A1 (de) * | 2005-08-04 | 2007-04-05 | Intendis Gmbh | Wasserfreies Mehr-Phasen-Gel-System |
GB2445539A (en) | 2006-12-29 | 2008-07-16 | Ardana Bioscience Ltd | Bigel composition |
US8475774B2 (en) | 2010-02-08 | 2013-07-02 | Johnson & Johnson Consumer Companies, Inc. | Sunscreen compositions comprising an ultraviolet radiation-absorbing polymer |
JP5903718B2 (ja) | 2010-08-09 | 2016-04-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Hiv−1感染の処置のための方法及び医薬的組成物 |
KR20230041081A (ko) | 2011-05-15 | 2023-03-23 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 바이오-접착제 겔 제형 및 남성의 성선기능저하증을 치료하기 위한 그의 용도 |
US11154535B2 (en) * | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
WO2014026707A1 (en) * | 2012-08-13 | 2014-02-20 | Edko Pazarlama Tanitim Ticaret Limited Sirketi | Anti-vaginitis compositions with improved release and adherence |
-
2017
- 2017-01-06 JP JP2018554642A patent/JP7055754B2/ja active Active
- 2017-01-06 AU AU2017206048A patent/AU2017206048B2/en active Active
- 2017-01-06 BR BR122023025444-9A patent/BR122023025444A2/pt active Search and Examination
- 2017-01-06 KR KR1020187022738A patent/KR20180117103A/ko not_active Application Discontinuation
- 2017-01-06 EP EP17736445.2A patent/EP3399963B1/en active Active
- 2017-01-06 IL IL300437A patent/IL300437A/en unknown
- 2017-01-06 GB GB1700220.5A patent/GB2551598B/en active Active
- 2017-01-06 EP EP22179555.2A patent/EP4091601A1/en active Pending
- 2017-01-06 ES ES17736445T patent/ES2949053T3/es active Active
- 2017-01-06 CN CN201780015750.8A patent/CN108712901A/zh active Pending
- 2017-01-06 US US15/400,517 patent/US20170196896A1/en not_active Abandoned
- 2017-01-06 CA CA3010829A patent/CA3010829A1/en active Pending
- 2017-01-06 MX MX2018008467A patent/MX2018008467A/es unknown
- 2017-01-06 WO PCT/US2017/012564 patent/WO2017120492A1/en active Application Filing
-
2018
- 2018-07-06 MX MX2022008277A patent/MX2022008277A/es unknown
- 2018-07-08 IL IL260462A patent/IL260462B2/en unknown
-
2021
- 2021-05-18 US US17/323,496 patent/US20210338693A1/en active Pending
-
2022
- 2022-04-06 JP JP2022063361A patent/JP2022088646A/ja active Pending
-
2023
- 2023-03-20 AU AU2023201712A patent/AU2023201712A1/en active Pending
-
2024
- 2024-04-08 JP JP2024062228A patent/JP2024083507A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3399963B1 (en) | 2023-06-07 |
AU2017206048A1 (en) | 2018-08-16 |
MX2018008467A (es) | 2019-01-10 |
JP2022088646A (ja) | 2022-06-14 |
IL260462B2 (en) | 2023-07-01 |
AU2023201712A1 (en) | 2023-04-20 |
IL260462A (es) | 2018-08-30 |
EP3399963A4 (en) | 2019-09-04 |
GB2551598B (en) | 2022-03-09 |
ES2949053T3 (es) | 2023-09-25 |
US20170196896A1 (en) | 2017-07-13 |
JP2024083507A (ja) | 2024-06-21 |
US20210338693A1 (en) | 2021-11-04 |
CN108712901A (zh) | 2018-10-26 |
GB2551598A (en) | 2017-12-27 |
CA3010829A1 (en) | 2017-07-13 |
KR20180117103A (ko) | 2018-10-26 |
EP3399963C0 (en) | 2023-06-07 |
IL260462B1 (en) | 2023-03-01 |
EP3399963A1 (en) | 2018-11-14 |
JP2019505583A (ja) | 2019-02-28 |
IL300437A (en) | 2023-04-01 |
GB201700220D0 (en) | 2017-02-22 |
JP7055754B2 (ja) | 2022-04-18 |
BR112018013979A2 (pt) | 2018-12-11 |
EP4091601A1 (en) | 2022-11-23 |
AU2017206048B2 (en) | 2023-04-13 |
WO2017120492A1 (en) | 2017-07-13 |
BR122023025444A2 (pt) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008277A (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
JO3522B1 (ar) | تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له | |
WO2015023649A3 (en) | Peptides for enhancing transdermal delivery | |
EP4349414A3 (en) | Methods and formulations for transdermal administration | |
CL2015002835A1 (es) | Nuevos derivados de piridina | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
WO2014153385A3 (en) | Methods of treating metabolic disorders | |
IN2014MN02269A (es) | ||
PH12018500910A1 (en) | Novel method of use and compositions | |
MX2015013187A (es) | Composiciones de anfetamina transdermica estable y metodos de fabricacion. | |
WO2008116004A3 (en) | Transdermal patch and method for delivery of vitamin b12 | |
WO2016182277A3 (ko) | 나노다이아몬드를 이용한 생리 활성물질의 경피 전달 방법 | |
MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
MX2015010967A (es) | Formulaciones transdermicas de laquinimod. | |
MX2016011706A (es) | Formulaciones de progesterona. | |
IN2014DN10134A (es) | ||
MX2018009739A (es) | La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas. | |
PH12016501500B1 (en) | Topical formulations of heparin | |
EP3823674A4 (en) | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF | |
BR112014018426A8 (pt) | Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina | |
NZ702849A (en) | Genotype- or phenotype-based drug formulation | |
IN2014MU00667A (es) |